Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Johanna Estrada et al.|Cancer Cell|2014Cited by 366